CLINICAL AND ECONOMIC EVALUATION OF ERIBULIN EFFECTIVENESS IN SOFT TISSUE SARCOMA: RESULTS OF META-ANALYSIS

CLINICAL AND ECONOMIC EVALUATION OF ERIBULIN EFFECTIVENESS IN SOFT TISSUE SARCOMA: RESULTS OF META-ANALYSIS

Innovative drugs eribulin and trabectedin are effective in the treatment of soft tissue sarcomas (STS) – rare, but severe malignancies.Aim of the study. To perform the pharmacoeconomic evaluation of these two agents used with the second and subsequent lines of chemotherapy in common/metastatic STS,...

Full description

Bibliographic Details
Main Authors:	P. V. Мazin, I. V. Sheshunov, N. K. Mazina, E. M. Markova
Format:	Article
Language:	Russian
Published:	IRBIS LLC 2017-05-01
Series:	Фармакоэкономика
Subjects:	eribulin trabectedin dacarbazine soft tissue sarcoma adverse event side effect meta-analysis direct comparison indirect comparison chemotherapy pharmacoeconomics willingness to pay threshold
Online Access:	https://www.pharmacoeconomics.ru/jour/article/view/178

Similar Items

Clinical Outcome of Systemic Treatment for Advanced Soft Tissue Sarcoma: Real-Life Perspective in Japan
by: Nakamura T, et al.
Published: (2020-10-01)

Recent Advances in the Treatment of Metastatic Soft Tissue Sarcoma
by: Elizabeth J. Davis, et al.
Published: (2018-12-01)

Advances in the treatment of soft tissue sarcoma: focus on eribulin
by: Koliou P, et al.
Published: (2018-02-01)

Eribulin in the management of inoperable soft-tissue sarcoma: patient selection and survival
by: Thomas C, et al.
Published: (2016-09-01)

Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin
by: Desar IME, et al.
Published: (2016-08-01)

The value of trabectedin in the treatment of soft tissue sarcoma
by: Nakamura T, et al.
Published: (2016-01-01)

Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group
by: Emanuela Palmerini, et al.
Published: (2021-03-01)

Trabectedin for Metastatic Soft Tissue Sarcoma: A Retrospective Single Center Analysis
by: Anthony D. Ho, et al.
Published: (2010-10-01)

Activity of Eribulin in a Primary Culture of Well-Differentiated/Dedifferentiated Adipocytic Sarcoma
by: Alessandro De Vita, et al.
Published: (2016-12-01)

Budget impact of eribulin in metastatic breast cancer in Russian Federation
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
by: Audrey Laroche, et al.
Published: (2017-04-01)

Trabectedin in Soft Tissue Sarcomas
by: Bradley J. Petek, et al.
Published: (2015-02-01)

The Use of Positron Emission Tomography in Soft Tissue Sarcoma Patients under Therapy with Trabectedin
by: Gerlinde Egerer, et al.
Published: (2009-07-01)

Combination of Trabectedin and Gemcitabine for Advanced Soft Tissue Sarcomas: Results of a Phase I Dose Escalating Trial of the German Interdisciplinary Sarcoma Group (GISG)
by: Bernd Kasper, et al.
Published: (2015-01-01)

Neoadjuvant Trabectedin plus Radiotherapy in High-Grade Sarcoma of the Leg: A Case Report
by: António José Loureiro da Silva, et al.
Published: (2018-07-01)

Validation of Neutrophil Count as An Algorithm-Based Predictive Factor of Progression-Free Survival in Patients with Metastatic Soft Tissue Sarcomas Treated with Trabectedin
by: Alexandre de Nonneville, et al.
Published: (2019-03-01)

Trabectedin Drug Holiday and Rechallenge in Soft Tissue Sarcomas: Report of 4 Cases and Literature Review
by: Francesco Pierantoni, et al.
Published: (2019-07-01)

Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center
by: Nadia Hindi, et al.
Published: (2020-12-01)

<i>CUL4A</i>, <i>ERCC5</i>, and <i>ERCC1</i> as Predictive Factors for Trabectedin Efficacy in Advanced Soft Tissue Sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) Study
by: David S. Moura, et al.
Published: (2020-04-01)

Eribulin drug review
by: Nishitha Shetty, et al.
Published: (2014-01-01)

Impact of Pathological Stratification on the Clinical Outcomes of Advanced Well-Differentiated/Dedifferentiated Liposarcoma Treated with Trabectedin
by: Chiara Fabbroni, et al.
Published: (2021-03-01)

Severe Rhabdomyolysis during Treatment with Trabectedin in Combination with a Herbal Drug in a Patient with Metastatic Synovial Sarcoma: A Case Report
by: Angela Damato, et al.
Published: (2017-03-01)

Trabectedin in Advanced Sarcomas—Experience at a Tertiary Care Center and Review of Literature
by: Saurav Verma, et al.
Published: (2021-04-01)

A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study
by: Javier Martínez-Trufero, et al.
Published: (2021-02-01)

Novel Insights into the Immunotherapy of Soft Tissue Sarcomas: Do We Need a Change of Perspective?
by: Andrej Ozaniak, et al.
Published: (2021-08-01)

PERAMPANEL EFFECTIVENESS IN THE TREATMENT OF REFRACTERY PARTIAL ONSET EPILEPSY WITH OR WITHOUT SECONDARY GENERALIZATION: PHARMACOECONOMIC ANALYSIS FOR THE RUSSIAN FEDERATION HEALTH CARE SYSTEM
by: N. K. Mazina, et al.
Published: (2017-05-01)

Efficacy and safety of eribulin in HER2-negative metastatic breast cancer: the results of long-term experience in real clinical practice in Russia
by: Vera A Gorbunova, et al.
Published: (2019-03-01)

Eribulin and Confusion: A Previously Unknown Drug Side-Effect
by: Abu Baker Sheikh, et al.
Published: (2020-06-01)

Eribulin for the treatment of anthracyclineand taxane-resistant breast cancer: a big step forward towards problem solving
by: E V Artamonova
Published: (2017-09-01)

The results of the first retrospective data analysis of eribulin application in patients with metastatic breast cancer in actual clinical practice in Russia
by: L V Bolotina, et al.
Published: (2016-09-01)

Pharmacoeconomic comparison of insulin glargine and insulin detemir in diabetes mellitus type 2
by: I. N. Dyakov, et al.
Published: (2020-05-01)

Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective
by: Yuan P, et al.
Published: (2021-02-01)

Stathmin dynamics modulate the activity of eribulin in breast cancer cells
by: Mikihiro Yoshie, et al.
Published: (2021-08-01)

PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
by: Ymera Pignochino, et al.
Published: (2017-04-01)

The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study
by: Elena I. Kovalenko, et al.
Published: (2020-05-01)

Marine-Derived Anticancer Agents: Clinical Benefits, Innovative Mechanisms, and New Targets
by: Renato B. Pereira, et al.
Published: (2019-06-01)

A Retrospective Evaluation of Eribulin Dosing Schedules in Metastatic Breast Cancer
by: Gagliardo, Camille, et al.
Published: (2016)

Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer
by: Renaud Sabatier, et al.
Published: (2021-03-01)

Efficacy of eribulin in breast cancer: a short report on the emerging new data
by: Eslamian G, et al.
Published: (2017-02-01)

Soft tissue sarcomas: Evaluation by immunohistochemistry
by: Ibtisam Hussein Al Obaidi
Published: (2020-06-01)

Cannot write session to /tmp/vufind_sessions/sess_ndqt5agt3iqo8lrve7cvff37p2